NCT05082688View on ClinicalTrials.gov

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

May 17, 2023

Study Completion Date

May 17, 2023

Conditions
InfluenzaHerpes Zoster
Interventions
BIOLOGICAL

Herpes zoster vaccination (Shingrix, GSK)

Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations

BIOLOGICAL

Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)

Fluarix Tetra is a quadrivalent inactivated influenza vaccine

BIOLOGICAL

Placebo

0.9% NaCl

Trial Locations (1)

6525GA

Radboud University, Nijmegen

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT05082688 - Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX) | Biotech Hunter | Biotech Hunter